SCHEMBL4917217

SCHEMBL4917217

CC(=O)O[C@@H]1COC(=O)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.40
HTT P42858 1/20 0.38
POLB P06746 1/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
XPO1 O14980 1/20 0.34
CHRM2 P08172 2/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
TSHR P16473 1/20 0.32
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
GSK3B P49841 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5307393 1.00 PTPN1 (0.40) PTPN1HTTPOLBKDM4ELMNA
SCHEMBL4926758 1.00 PTPN1 (0.40) PTPN1HTTPOLBKDM4ELMNA
SCHEMBL13496330 0.82 PTPN1 (0.36) PTPN1HTTKDM4ELMNAMAPT
SCHEMBL76528 0.82 ALDH1A1 (0.39) PTPN1HTTPOLBKDM4ELMNA
SCHEMBL26300297 0.81 CYP1A2 (0.39) POLBCHRM2CHRM4CHRM5CHRM1
SCHEMBL16691271 0.81 PTPN1 (0.38) PTPN1HTTKDM4ELMNAMAPT
SCHEMBL15216845 0.81 PTPN1 (0.38) PTPN1HTTKDM4ELMNAMAPT
SCHEMBL5898372 0.80 PTPN1 (0.40) PTPN1HTTKDM4ELMNAMAPT
SCHEMBL5898366 0.80 PTPN1 (0.40) PTPN1HTTKDM4ELMNAMAPT
SCHEMBL9925264 0.79 PTPN1 (0.37) PTPN1HTTKDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390825-B1 Process for the preparation of oxazolidinones and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-06-24 US disclosed
US-20080146458-A1 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-06-19 US disclosed
US-20070265451-A1 Process for the preparation of oxazolidinones and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2007-11-15 US disclosed
WO-2007035066-A1 THE METHOD OF MAKING OPTICALLY ACTIVE 3-ACYLOXY-GAMMA-BUTYROLACTONE AND OPTICALLY ACTIVE 3-HYDROXY-GAMMA-BUTYROLACTONE BY ENZYMATIC METHOD ENZYTECH, LTD. (KR) 2007-03-29 WO disclosed
EP-1578723-A4 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF UNIV MICHIGAN STATE (US) 2006-11-02 EP disclosed
EP-1578723-A3 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF MICHIGAN STATE UNIVERSITY (US) 2005-10-20 EP disclosed
EP-1578723-A2 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF MICHIGAN STATE UNIVERSITY (US) 2005-09-28 EP disclosed
US-6713290-B2 GENERATING PREFERENTIAL PARTICLE; INCUBATE STARCH AND OLIGOSACCHARIDE, OXIDIZE MIXTURE, CYCLIZE MIXTURE, RECOVER PREFERENTIAL COMPOUND SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2004-03-30 US disclosed
CN-1483730-A 'Beta'-substituted-'gamma'-butyrolactone 鱼洪善 2004-03-24 CN disclosed
EP-1398312-A1 Beta-substituted-gamma-butyrolactones and a process for preparation thereof Uh, Hong-Sun (KR) 2004-03-17 EP disclosed
EP-1100954-A1 CONTINUOUS PROCESS FOR PREPARING OPTICALLY PURE (S)-3,4-DIHYDROXYBUTYRIC ACID DERIVATIVES Samsung Fine Chemicals Co., Ltd. (KR) 2001-05-23 EP disclosed
EP-1100953-A1 CONTINUOUS PROCESS FOR PREPARING OPTICALLY PURE ($i(S))-3-HYDROXY-GAMA-BUTYROLACTONE Samsung Fine Chemicals Co., Ltd. (KR) 2001-05-23 EP disclosed
EP-1100948-A1 PROCESS FOR PREPARING ALPHA-(1,4) LINKED OLIGOSACCHARIDE Samsung Fine Chemicals Co., Ltd. (KR) 2001-05-23 EP disclosed
US-6221639-B1 FROM POLYSACCHARIDE SOURCE BY SELECTIVE ENZYMATIC DEGRATION OF AMYLOPECTIN TO ALPHA-(1,4) LINKED OLIGOSACCHARIDE; AND OXIDATION IN BASE AND SUBSEQUENT ESTERIFICATION WITH AN ALCOHOL IN THE PRESENCE OF AN ACID CATALYST SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2001-04-24 US disclosed
US-6124122-A PREPARING ALPHA-(1,4) LINKED OLIGOSACCHARIDE WITH ADEQUATE SUGAR DISTRIBUTION BY REACTING AMYLOPECTIN EASILY AVAILABLE FROM NATURAL PRODUCT WITH ENZYME UNDER A SPECIFIC CONDITION AND PERFORMING OXIDATION, ESTERIFICATION AND CYCLIZATION SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2000-09-26 US disclosed
WO-2000005399-A1 PROCESS FOR PREPARING OPTICALLY PURE (S)-3-HYDROXY-GAMA-BUTYROLACTONE SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2000-02-03 WO disclosed
WO-2000005401-A1 CONTINUOUS PROCESS FOR PREPARING OPTICALLY PURE (S)-3-HYDROXY-GAMA-BUTYROLACTONE SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2000-02-03 WO disclosed
WO-2000005398-A1 PROCESS FOR PREPARING ALPHA-(1,4) LINKED OLIGOSACCHARIDE SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2000-02-03 WO disclosed
WO-2000005402-A1 CONTINUOUS PROCESS FOR PREPARING OPTICALLY PURE (S)-3,4-DIHYDROXYBUTYRIC ACID DERIVATIVES SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2000-02-03 WO disclosed
WO-2000005400-A1 PROCESS FOR PREPARING OPTICALLY PURE (S)-3,4-DIHYDROXYBUTYRIC ACID DERIVATIVES SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265451-A1 Process for the preparation of oxazolidinones and method of use thereof OXA1L, OTC, ODC1 PTPN1 2342/4885HTT 4763/4885POLB 364/4885
US-20080146458-A1 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF OXA1L, OGFOD1, CYP51A1 PTPN1 3805/4885HTT 4798/4885POLB 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.